PTN

Across TCGA pan-cancer cohorts, PTN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTN data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTN expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where PTN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.865	0.388	.004	37	view →
LSCC	DFS	Quartile	All	0.723	0.946	.016	9	view →
HNSC	DFS	Median	III,IV	0.885	0.688	.008	6	view →
CCRCC	OS	Quartile	III,IV	0.558	0.989	.027	2	view →
LUAD	DFS	Tertile	All	0.860	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTN–PDAC (DFS)

Open the PDAC breakdown →